A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09

PURPOSE: Pegylated granulocyte-colony-stimulating factor (G-CSF) is frequently used to prevent febrile neutropenia (FN) in patients undergoing chemotherapy with a high risk of myelosuppression. This phase II/III study was conducted to determine the adequate dose of pegteograstim, a new formulation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ki Hyeong, Kim, Ji-Yeon, Lee, Moon Hee, Han, Hye Sook, Lim, Joo Han, Park, Keon Uk, Park, In Hae, Cho, Eun Kyung, Yoon, So Young, Kim, Jee Hyun, Choi, In Sil, Park, Jae Hoo, Choi, Young Jin, Kim, Hee-Jun, Jung, Kyung Hae, Kim, Si-Young, Oh, Do-Youn, Im, Seock-Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766213/
https://www.ncbi.nlm.nih.gov/pubmed/26423618
http://dx.doi.org/10.1007/s00520-015-2963-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766213/
https://www.ncbi.nlm.nih.gov/pubmed/26423618
http://dx.doi.org/10.1007/s00520-015-2963-7

Ejemplares similares